A trial update dated August 14, 2026 reports on a study titled "Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)." The study, registered as NCT07179380, is listed as a Phase 3 trial. Its current status is recruiting. The trial is designed to examine treprostinil palmitil inhalation powder, referred to as TPIP, in participants who have pulmonary hypertension associated with interstitial lung disease, a condition abbreviated as PH-ILD. No results have been posted for this trial at this time. This update reflects only the trial's registration details, including its phase and recruitment status, as listed on ClinicalTrials.gov. No efficacy or safety outcomes are described in this update. Individuals interested in this study can find further details, including eligibility criteria and contact information, through the official trial registry listing. This news brief does not include information beyond what is stated in the trial registration record. Readers seeking additional context about this compound and its research history can consult the compound overview.
Phase 3 Trial of Treprostinil Palmitil Inhalation Powder Now Recruiting
See the full nesiritide overview
Source: https://clinicaltrials.gov/study/NCT07179380